Aptose Biosciences Inc's stock remains steady this week amid ongoing developments in its acquisition by Hanmi Pharmaceutical.
Aptose Biosciences Inc (APS.TO) has experienced no significant price movement this week, closing at C$2.40 with a 1D change of 0.00%. Over the past month, the stock has gained 9.09%, and year-to-date, it has risen by 18.81%. Despite this stability, the market is closely watching the company's strategic developments, particularly its acquisition by Hanmi Pharmaceutical.
Investor takeaway: Investors should stay alert to Aptose's ongoing acquisition process and any clinical updates that may impact its stock performance. The lack of major news this week suggests a period of consolidation as the company navigates its future direction.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Aptose Biosciences Inc
APS.TO
APS.TO
Aptose Biosciences Inc
WealthAwesomeMarket cap
$6.13M
52W high
$2.59
52W low
$1.41
1W change
+0.00%
Beta
0.34
Analyst Price Targets
Based on analyst covering APS
Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.36
-1.7% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$2.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.40 | C$2.00 – C$2.88 |
| 60 trading days | C$2.40 | C$1.86 – C$3.10 |
| 90 trading days | C$2.40 | C$1.75 – C$3.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Aptose's stock closed at C$2.40, remaining unchanged this week.
The stock has shown a strong performance over the past month, increasing by 9.09%, indicating potential investor interest despite the absence of recent news.
Bull case
If the acquisition by Hanmi Pharmaceutical goes through, Aptose could gain valuable resources and support. This might speed up its clinical development and enhance its market presence.
Bear case
On the other hand, Aptose's negative return on equity and ongoing lack of profitability may raise red flags for investors regarding its long-term viability, especially in a competitive healthcare landscape.
Price Action Overview
Aptose Biosciences Inc's stock has remained flat this week, closing at C$2.40. The stock has shown a month-to-date increase of 9.09% and a year-to-date gain of 18.81%. This stability may indicate investor confidence as the company progresses through its acquisition by Hanmi Pharmaceutical.
Recent Company News
Currently, there are no major news announcements impacting Aptose Biosciences this week. However, the company has been in the spotlight following the completion of its acquisition by Hanmi Pharmaceutical announced on June 30, 2026. This strategic move is expected to shape the company's future trajectory.
Technical Picture
From a technical standpoint, Aptose's stock is currently trading above its 50-day moving average of C$2.25, which is a positive sign (+6.4% vs. price). The 200-day moving average stands at C$2.14 (+12.3% vs. price), indicating a longer-term upward trend. The stock's 52-week range is C$1.41 to C$2.59, suggesting it is trading at 84% of its range. With a beta of 0.34, the stock is considered less volatile than the market, which may appeal to conservative investors.
Advertisement
Wealth Awesome Newsroom
The Wealth Awesome Newsroom delivers timely Canadian market updates, earnings, dividends, and stock movers for DIY investors. Coverage is reviewed against public filings and market data feeds.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
